Kentucky Retirement Systems bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,875 shares of the life sciences company's stock, valued at approximately $863,000.
A number of other institutional investors and hedge funds have also modified their holdings of ILMN. Rakuten Securities Inc. increased its stake in shares of Illumina by 290.3% during the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after purchasing an additional 270 shares in the last quarter. Center for Financial Planning Inc. acquired a new position in Illumina during the first quarter worth about $33,000. Fourth Dimension Wealth LLC acquired a new position in Illumina during the fourth quarter worth about $40,000. PFS Partners LLC boosted its position in Illumina by 400.0% during the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock worth $40,000 after acquiring an additional 400 shares during the last quarter. Finally, Assetmark Inc. boosted its position in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.
Illumina Stock Up 1.0%
ILMN stock traded up $0.93 during midday trading on Thursday, hitting $94.16. The company's stock had a trading volume of 2,928,129 shares, compared to its average volume of 2,147,886. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The firm has a 50-day simple moving average of $81.76 and a 200-day simple moving average of $100.05. The company has a quick ratio of 1.48, a current ratio of 1.86 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $14.91 billion, a P/E ratio of -15.51, a PEG ratio of 1.80 and a beta of 1.32.
Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same period last year, the business posted $0.98 earnings per share. Illumina's revenue was down 1.4% compared to the same quarter last year. As a group, equities analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on the stock. Piper Sandler lowered their price target on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a research report on Thursday, May 15th. Stephens reiterated an "overweight" rating and issued a $105.00 target price on shares of Illumina in a report on Tuesday, May 20th. Guggenheim decreased their target price on shares of Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Canaccord Genuity Group boosted their target price on shares of Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a report on Wednesday, June 11th. Finally, Royal Bank Of Canada decreased their target price on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $127.39.
Check Out Our Latest Research Report on Illumina
Insider Transactions at Illumina
In other Illumina news, CFO Ankur Dhingra acquired 6,100 shares of the stock in a transaction dated Monday, May 12th. The stock was acquired at an average cost of $81.21 per share, with a total value of $495,381.00. Following the transaction, the chief financial officer now owns 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.60% of the company's stock.
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Stories
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
